Kolon announced on the 3rd that it will additionally acquire 373,420 shares of its U.S. subsidiary Kolon TissueGene for approximately 44.1 billion KRW.
After the stock acquisition, Kolon's stake in Kolon TissueGene will be 39.8%. The scheduled date for the stock acquisition is the 13th.
Kolon stated that the purpose of this stock acquisition is "to raise operating funds such as clinical costs for Kolon TissueGene."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
